Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12M Series A Funding
Summary
SACRAMENTO, Calif., May 19, 2025 /PRNewswire/ -- Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today announced the launch of its innovative Cloud Lab platform following the successful closure of an oversubscribed $12 million Series A financing round. "Persist dramatically reduces both the time and cost at every stage of development, ultimately lowering the hurdle for investment in next-generation therapeutics like long-acting injectables. In a recent project with a major pharmaceutical client, Persist AI demonstrated the power of its platform by identifying an optimal long-acting injectable formulation in just two monthsa process that traditionally takes a year or longer. "Through the newly launched Cloud Lab, pharmaceutical companies worldwide can now remotely build and test formulations on Persists advanced robotic facilities to develop:The platform supports a wide range of modalities including peptides, small molecules, antibodies, and anti-sense oligonucleotides, currently serving multiple top 10 pharmaceutical clients and several smaller biotechs developing next-generation treatments for chronic diseases.The $12 million in Series A funding will support several key initiatives. Prior to founding Persist, Raman was part of the automation team at Zymergen, developing the next generation robotic factory for synthetic biology.